The global skeletal dysplasia market size is expected to reach USD 3.6 billion by 2026, according to a new report by Grand View Research, Inc., registering a 4.0% CAGR over the forecast period. Increasing prevalence of this condition, especially in children, and growing adoption of orphan drugs are likely to contribute to the expansion of the market.
Among different disorders, achondroplasia is the most common condition. According to estimates published by the National Human Genome Research Institute in 2016, achondroplasia occurs in 1 in 15,000-40,000 live births. Although there are no current therapies approved specifically for achondroplasia, there are five therapies under clinical development.
Genetic defects attributable to the disorder include spontaneous mutations in the FGFR3 gene. Vosoritide by BioMarin targets inhibition of the FGFR3 pathway and presents a first-in-class drug for achondroplasia. The drug is in phase III clinical trial and is expected to enter the market in 2024. Clementia (Ipsen Group) and Regeneron are other market players targeting disorders such as multiple osteochondromas and fibrodysplasia ossificans progressiva (FOP). Approval of these pipeline therapies with orphan drug status during the forecast period will further support skeletal dysplasia market growth.
The medicines vary depending on the genetic cause of the disorder and only a handful of the disorders, such as XLH and hypophosphatasia, have approved curative therapies, including Ultragenyx Pharmaceuticals’ Crysvita and Alexion Pharmaceuticals’ Strensiq, respectively.
Crysvita received FDA approval in 2018 whereas Strensiq received approval in 2015. The sales of Strensiq increased from USD 12.0 million in 2015 to USD 475.1 million in 2018. Higher uptake of these orphan drugs signal growth of the market.
Access Full Informative Content Copy @
Further key findings from the report suggest:
- Depending on the disorder, patients develop multiple symptoms ranging from spinal deformities to abnormal dental development. These disorders limit mobility and functional abilities in patients
- Commonly occurring deformities in these disorders include abnormal skeletal development that require orthopedic procedures and other interventions to relieve movement obstructions
- Early identification is crucial for timely medical management. The treatment for skeletal dysplasia is restricted largely to supportive care
- Surgical therapy is the most effective treatment option for achondroplasia type segment of skeletal dysplasia market. There is currently no definitive treatment for FOP. However, a brief course of high-dose corticosteroids, such as Prednisone, may help reduce intense inflammation and tissue swelling seen in early stages.
Inquire to Our Experts for Buy This Content @ https://www.grandviewresearch.com/inquiry/5748/ibb
Grand View Research has segmented the global skeletal dysplasia market based on type, treatment, and region:
Skeletal Dysplasia Type Outlook (Revenue, USD Million, 2015 – 2026)
- X-linked hypophosphatemia
- Fibrodysplasia ossificans progressive
- Multiple osteochondromas
Skeletal Dysplasia Treatment Outlook (Revenue, USD Million, 2015 – 2026)
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. GVR’s Internal Database
1.3.3. Secondary Sources & Third-Party Perspectives
1.3.4. Primary research
1.4. Information Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Data Visualization
1.6. Data Validation & Publishing
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Global Skeletal Dysplasia Market Variables, Trends & Scope
3.1. Skeletal Dysplasia Market Lineage outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market Driver Analysis
184.108.40.206. Increasing prevalence of skeletal dysplasia
220.127.116.11. Presence of pipeline products
3.3.2. Market Restraint Analysis
Browse Related Report
Medical Foods Market Size, Share & Trends Analysis By Route Of Administration (Oral, Enteral), By Product (Pills, Powders, Others), By Application, By Sales Channel (Retail, Online, Institutional), And Segment Forecasts, 2019 – 2025
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
Country: United States